2020-2027 Analysis and Review Manidipine Hydrochloride Market
Manidipine Hydrochloride Market By Clinical Application (Moderate Hypertension and Renal Protection in Type 2 Diabetes), By Treatment Regimen (Monotherapy and Combination Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The manidipine hydrochloride market was valued at USD 393.5 Mn by 2019. A constant rise in the consumption of alcohol, tobacco, unhealthy diet, stress giving rise to mild to moderate hypertension in the young adult population worldwide. A significant increase in the renal complication in elderly patients having preexisting comorbidities of type 2 diabetes and hypertension drives the manidipine hydrochloride market growth.
Manidipine hydrochloride is a dihydropyridine that is classified as a calcium channel blocker that is used as an antihypertensive agent that produces vasodilation of the vascular smooth muscles to lower the peripheral blood pressure. At clinically relevant dosage it does not produce any effect on the central nervous system and heart.
The major segments related to the manidipine hydrochloride market are:
By Clinical Application (2017–2027; US$ Mn)
Moderate Hypertension
Renal Protection in Type 2 Diabetes
By Treatment Regimen (2017–2027; US$ Mn)
Monotherapy
Combination Therapy
Geography Segment (2017–2027; US$ Mn)
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
The study includes the profiles of major market players with a significant global and regional presence along with top company positioning
Significant customers?
Segment Analysis
Moderate hypertension is presently reigning the clinical application segment for the manidipine hydrochloride market. As per the research citings provided by the World Health Organization (WHO), each year approximately 17 million people die worldwide due to cardiovascular complications. Furthermore, it is estimated that 50% of the patients suffering from moderate hypertension are subjected to suffer from myocardial infarction or stroke if proper treatment regimen is not followed. Renal protection in type 2 diabetes will be the fastest-growing application segment during the forecast period. Renal impairment is a common clinical manifestation in type 2 diabetic patients with hypertension (serum creatinine levels ≤ 3 mg/dl) who are above 50 years of age. Clinical trials have shown positive evidences that manidipine has lower urinary albumin excretion rate and has a lower risk of ankle edema in comparison to other calcium channel blockers.
Currently monotherapy is leading the treatment regimen segment for the manidipine hydrochloride market. Manidipine 10-20mg once daily is prescribed for patients suffering from moderate hypertension. Combination therapy is gaining tremendous traction in the last 2 decades owing to a significant increase in the number of patients suffering from renal complication with preexisting comorbidities if type 2 diabetes and hypertension. Delapril 30mg/manidipine 10mg is prescribed for its ability to manage renal complications in type diabetic patients with hypertension.
Europe is currently spearheading the regional segment for the manidipine hydrochloride market. Rising prevalence of lifestyle disorders such as cardiovascular disease, diabetes, etc. primarily drives the manidipine hydrochloride market growth in the region. As per the latest research citings provided by the European Heart Network (EHN), approximately 37% of the deaths recorded in the European Union is associated with cardiovascular complication. Domicile of major players such as Chiesi Farmaceutici s.p.a., Takeda Italia SpA, Bennett SA, Mylan Pharmaceutical Industries Ltd., etc. further propel the market growth in the region. The USFDA has not recommended the use of manidipine hydrochloride in North America. It is anticipated that in the near future Asia Pacific will be registering remarkable market growth on account of rising prevalence of geriatric population suffering from renal impairment and preexisting hypertension. Effective implementation of treatment guidelines pertaining to hypertension management further accentuates the manidipine hydrochloride market growth in the Asia Pacific.
$4,600 | |
$6,600 | |
$13,200 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |